[Validity of hepato-biliary functional scintigraphy using 99mTc-diethyl-IDA (author's transl)]

Current imaging techniques for liver and bile function lack precision in distinguishing specific pathologies. While prior research has shown that radiopharmaceuticals can track biliary excretion, uncertainty remains about their reliability in diagnosing hepatic impairments. Established methods often fail to differentiate between intrahepatic and extrahepatic issues. This gap motivated the search for a more specific tracer. No prior work had resolved how best to measure functional clearance versus morphological anomalies. The diagnostic relevance of time-parameters in individual cases remains unresolved. This paper's contribution lies in evaluating a new radiopharmaceutical's performance. The study addresses the need for better tools to assess hepato-biliary function. It builds on existing knowledge of radiopharmaceutical behavior in the liver.

The study aimed to assess the validity of hepato-biliary functional scintigraphy using 99mTc-diethyl-IDA (99mTc-DAIDA). The specific problem addressed is the lack of reliable imaging tools to distinguish between various liver diseases. Researchers focused on evaluating how well this radiopharmaceutical tracks biliary excretion. The motivation stems from the need for clearer diagnostics in hepatic impairments. The study sought to determine if 99mTc-DAIDA could provide reproducible time-parameters. It also aimed to assess its diagnostic relevance in individual cases. The goal was to compare this tracer against existing methods. The study's design targeted a selected patient cohort for accuracy.

The study involved hepato-gastroenterologically selected patients (n = 45) to evaluate 99mTc-DAIDA's performance. Researchers used hepato-biliary sequential scintigraphy with this radiopharmaceutical. They measured liver function parameters like Tmax, T/2, and excretion times. The analysis included comparisons of defining regions and calculation types. Radiochromatographic examinations confirmed the tracer's excretion as an unchanged anion. The team calculated clearance rates and renal excretion percentages. They categorized patients based on hepatic and biliary status. The methodology focused on quantifying functional and morphological outcomes.

99mTc-DAIDA demonstrated superior performance compared to other cholotropic radiopharmaceuticals. In patients without hepato-biliary disease, the mean Tmax was 15.5 ± 5.2 minutes. The T/2 value averaged 30.8 ± 8.2 minutes, and gallbladder appearance occurred at 13.5 ± 6.1 minutes. Duodenal excretion time was 22.0 ± 10.8 minutes. Clearance rates averaged 323.8 ± 145.8 ml/min x 1.73 m². Renal excretion accounted for 5.15% of injected activity within 51 minutes. Patients with intrahepatic jaundice showed significantly increased time parameters. Extrahepatic jaundice patients had undetermined function values due to variability.

The study suggests that 99mTc-DAIDA is a reliable tracer for hepato-biliary scintigraphy. The authors propose that this radiopharmaceutical may find its main use in morphologic diagnostics. The data suggest that time-parameters and clearance rates may increase in intrahepatic jaundice. However, the authors note that these parameters may lack diagnostic relevance in individual cases. The findings may support the use of 99mTc-DAIDA in assessing biliary excretion. The study suggests that renal excretion remains minimal in comparison to biliary elimination. The authors propose that this tracer may offer advantages over other cholotropic agents. They conclude that further research may be needed to refine its clinical application.